- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00579371
Cadaveric Islet Transplantation in Patients With Insulin-Dependent Diabetes Mellitus
We hypothesize that the following improvements to islet transplantation will increase the islet mass successfully isolated and allow for engraftment from a single pancreas. The improvements are:
- Using Two-Layer method preservation to improve pancreas quality before islet isolation
- Maintaining isolated islets in culture before transplantation
- Using a steroid-free immunosuppression regimen
- Transplanting the best combination of donor and recipient possible after human leukocyte antigens (HLA) screening and final crossmatching
Study Overview
Status
Intervention / Treatment
Detailed Description
We hypothesize that the following improvements to islet transplantation will increase the islet mass successfully isolated and allow for engraftment from a single pancreas:
using Two-Layer method preservation to improve pancreas quality before islet isolation, maintaining isolated islets in culture before transplantation, using a steroid-free immunosuppression regimen, and transplanting the best combination of donor and recipient possible after HLA screening and final crossmatching.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198
- The Nebraska Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Group 1: Diagnosis of Type-1 diabetes mellitus for more than 5 years with at least one of the following complications:
- Metabolic lability/instability (two or more episodes of severe hypoglycemia) or two or more hospital visits for diabetic ketoacidosis during the previous year
- Progression of secondary complications of diabetes as determined by The Nebraska Medical Center/University of Nebraska Medical Center staff endocrinologists
- Group 2: Diagnosis of Type-1 diabetes with successful renal transplant on steroid-free, FK506/rapamycin-based immunosuppression
Exclusion Criteria:
- Severe co-existing cardiac disease
- Active alcohol or substance abuse, including cigarette smoking
- Psychiatric disorder making the subject not a suitable candidate for transplantation
- History of medical non-compliance
- Active infection, including hepatitis C and B, HIV, and tuberculosis (or suspected tuberculosis)
- Any history of malignancy except squamous or basal cell skin cancer
- BMI >28 kg/meter-squared, or body weight >80kg at screening visit, or >85kg on the day of transplantation (due to the difficulty of obtaining a sufficiently large islet mass to adequately treat either large patients or those whose obesity elevates their insulin needs)
- Positive C-peptide response to intravenous glucose tolerance test and Mixed Meal glucose tolerance test: any C-peptide >0.3 ng/mL post infusion
- Inability to provide informed consent
- Age less than 19 or greater than 70 years
- Creatinine clearance <60 mL/min/1.73 meter-squared for Group 1 and creatinine clearance <40 mL/min/1.73 meter-squared for Group 2 (those subjects currently on immunosuppression due to previous kidney transplant)
- Macroalbuminuria (urinary albumin excretion rate >300 mg/24h) for Group 1 and macroalbuminuria (urinary albumin excretion rate >600mg/24h) for Group 2
- Baseline Hb <10 gm/dL
- Baseline liver function tests outside of normal range
- Presence of gallstones or hemangioma in liver on baseline ultrasound exam
- Positive pregnancy test, intention of future pregnancy, or presently breast-feeding
- Evidence of sensitization on panel reactive antibodies (PRA)
- Insulin requirement >0.7 IU/kg/day or HbA1c >15%
- Hyperlipidemia
- Under treatment for a medical condition requiring chronic use of steroids
- Use of Coumadin or other anticoagulant therapy (except aspirin) or a prothrombin time/international normalized ratio (PT-INR) >1.5
- Diagnosis of Addison's disease
Additional Exclusion Criteria for Group 2 Subjects:
- Any history of organ transplantation other than kidney or pancreas
- Any previous graft lost to rejection
- Any history of early, multiple, or vascular renal allograft rejection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transplantation of Islets of Langerhans
Subjects will receive islets isolated from one donor pancreas per transplantation event.
Subjects will receive a cumulative dose of 8,000 International Units/kg.
Islets will be infused intraportally.
If necessary, additional transplantation events will be performed.
|
Subjects will receive islets isolated from one donor pancreas per transplantation event.
Subjects will receive a cumulative dose of 8,000IE/kg.
Islets will be infused intraportally.
If necessary, additional transplantation events will be performed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of insulin independence with a single islet transplant
Time Frame: 1 year post-transplantation
|
Incidence of insulin independence with a single transplantation measured at one year post-transplantation.
|
1 year post-transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Islet mass resulting in insulin independence/reduced exogenous insulin requirement
Time Frame: 1 year post-transplantation
|
Insulin independence or reduced exogenous insulin required measured at one year post-transplantation.
|
1 year post-transplantation
|
Graft survival
Time Frame: 3 years post-transplantation
|
The survival of the Islets of Langerhans graft as measured at three years post-transplantation.
|
3 years post-transplantation
|
Metabolic functional assessments of the islet graft
Time Frame: 3 years post-transplantation
|
An assessment of the metabolic function of the islet of Langerhans graft as measured three years post-transplantation.
|
3 years post-transplantation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: R Brian Stevens, MD PhD, University of Nebraska
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0149-03-XX
- BB IND 11397 (Other Identifier: FDA)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
Clinical Trials on Islets of Langerhans
-
University of MinnesotaAvailableHypoglycemia | Type 1 Diabetes Mellitus | End-stage Renal Disease | Labile DiabetesUnited States
-
CellTrans Inc.Approved for marketingType 1 Diabetes MellitusUnited States
-
University of MinnesotaJuvenile Diabetes Research Foundation; National Institutes of Health (NIH)CompletedHypoglycemia | Type 1 Diabetes MellitusUnited States
-
University of MinnesotaJuvenile Diabetes Research FoundationCompletedHypoglycemia | Type 1 DiabetesUnited States
-
University of VirginiaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Wyeth...UnknownDiabetes Mellitus, Type 1United States
-
University of MinnesotaJuvenile Diabetes Research Foundation; Roche Pharma AGCompletedHypoglycemia | Type 1 DiabetesUnited States
-
University of MinnesotaJuvenile Diabetes Research FoundationTerminatedHypoglycemia | Type 1 Diabetes MellitusUnited States
-
University of MinnesotaRecruitingDiabetes Mellitus | Chronic Pancreatitis | Islet Cell TransplantationUnited States
-
University of MinnesotaNovartis; Juvenile Diabetes Research Foundation; National Institutes of Health...CompletedHypoglycemia | Type 1 Diabetes MellitusUnited States
-
Emory UniversityJuvenile Diabetes Research FoundationCompletedDiabetes Mellitus, Type 1United States